X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4771) 4771
Book Review (610) 610
Publication (251) 251
Newsletter (20) 20
Book Chapter (7) 7
Magazine Article (6) 6
Conference Proceeding (4) 4
Newspaper Article (2) 2
Transcript (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4327) 4327
index medicus (4270) 4270
male (2871) 2871
female (2861) 2861
cytarabine - administration & dosage (2513) 2513
middle aged (2382) 2382
adult (2262) 2262
antineoplastic combined chemotherapy protocols - therapeutic use (1971) 1971
cytarabine - adverse effects (1858) 1858
oncology (1851) 1851
hematology (1773) 1773
aged (1665) 1665
antineoplastic combined chemotherapy protocols - adverse effects (1551) 1551
adolescent (1302) 1302
chemotherapy (1215) 1215
leukemia, myeloid, acute - drug therapy (1210) 1210
cytarabine (1136) 1136
treatment outcome (1033) 1033
cytarabine - therapeutic use (961) 961
remission induction (866) 866
cancer (827) 827
child (755) 755
antineoplastic combined chemotherapy protocols - administration & dosage (625) 625
etoposide - administration & dosage (604) 604
therapy (604) 604
abridged index medicus (592) 592
acute myelogenous leukemia (582) 582
leukemia (576) 576
acute myeloid leukemia (555) 555
prognosis (555) 555
child, preschool (549) 549
disease-free survival (497) 497
acute disease (480) 480
daunorubicin - administration & dosage (479) 479
cyclophosphamide - administration & dosage (472) 472
methotrexate - administration & dosage (471) 471
recurrence (469) 469
combined modality therapy (466) 466
acute myeloid-leukemia (463) 463
transplantation (453) 453
young adult (425) 425
vincristine - administration & dosage (418) 418
aged, 80 and over (407) 407
survival rate (405) 405
drug administration schedule (403) 403
retrospective studies (382) 382
leukemia, myeloid, acute - mortality (373) 373
antineoplastic agents - adverse effects (370) 370
survival analysis (355) 355
antineoplastic agents - therapeutic use (354) 354
follow-up studies (340) 340
medicine & public health (339) 339
dose-response relationship, drug (338) 338
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (329) 329
leukemia, myeloid - drug therapy (327) 327
care and treatment (326) 326
doxorubicin - administration & dosage (322) 322
leukemia - drug therapy (320) 320
infant (315) 315
methotrexate - adverse effects (310) 310
cytosine-arabinoside (309) 309
risk factors (308) 308
survival (303) 303
aml (297) 297
mitoxantrone - administration & dosage (285) 285
pharmacology & pharmacy (284) 284
animals (280) 280
etoposide - adverse effects (280) 280
time factors (274) 274
children (270) 270
antimetabolites, antineoplastic - adverse effects (266) 266
cyclophosphamide - adverse effects (264) 264
idarubicin - administration & dosage (264) 264
high-dose cytarabine (260) 260
research (260) 260
prednisone - administration & dosage (256) 256
stem cells (254) 254
daunorubicin - adverse effects (252) 252
hematopoietic stem cell transplantation (249) 249
acute lymphoblastic-leukemia (242) 242
antimetabolites, antineoplastic - administration & dosage (241) 241
trial (241) 241
stem-cell transplantation (237) 237
lymphoma, non-hodgkin - drug therapy (236) 236
transplantation, autologous (235) 235
hematology, oncology and palliative medicine (234) 234
salvage therapy (233) 233
etoposide (231) 231
vincristine - adverse effects (231) 231
low-dose cytarabine (227) 227
drug therapy, combination (226) 226
pediatrics (226) 226
toxicity (223) 223
prospective studies (221) 221
antineoplastic agents - administration & dosage (219) 219
health aspects (218) 218
bone-marrow-transplantation (216) 216
dosage and administration (216) 216
analysis (210) 210
dexamethasone - administration & dosage (210) 210
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4452) 4452
Japanese (96) 96
German (72) 72
French (52) 52
Chinese (33) 33
Spanish (32) 32
Russian (19) 19
Polish (17) 17
Italian (9) 9
Czech (6) 6
Portuguese (5) 5
Dutch (3) 3
Norwegian (3) 3
Hungarian (2) 2
Slovak (2) 2
Croatian (1) 1
Romanian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cell Cycle, ISSN 1538-4101, 05/2012, Volume 11, Issue 9, pp. 1851 - 1861
Journal Article
Blood, ISSN 0006-4971, 04/2007, Volume 109, Issue 8, pp. 3441 - 3450
Studies have documented the potential antitumor activities of oridonin, a compound extracted from medicinal herbs. However, whether oridonin can be used in the... 
MURINE MODEL | CELLS | APOPTOSIS | SINGLE INSTITUTIONS EXPERIENCE | GROWTH-INHIBITION | RETINOIC ACID | ACUTE MYELOID-LEUKEMIA | HEMATOLOGY | EXPRESSION | ACUTE PROMYELOCYTIC LEUKEMIA | ARSENIC TRIOXIDE | Chromosomes, Human, Pair 8 - genetics | Plant Extracts - chemistry | Translocation, Genetic | Oncogene Proteins, Fusion - metabolism | Cytarabine - pharmacology | Apoptosis - drug effects | Plant Extracts - pharmacology | Humans | Leukemia, Myeloid, Acute - metabolism | Neoplasms, Experimental - pathology | U937 Cells | Diterpenes - agonists | Leukemia, Myeloid, Acute - drug therapy | Antineoplastic Agents - pharmacology | Plant Extracts - agonists | Cytarabine - agonists | Diterpenes - chemistry | Diterpenes, Kaurane - chemistry | Diterpenes - pharmacology | Diterpenes, Kaurane - pharmacology | Plants, Medicinal - chemistry | Core Binding Factor Alpha 2 Subunit - metabolism | Core Binding Factor Alpha 2 Subunit - antagonists & inhibitors | Leukemia, Myeloid, Acute - pathology | Diterpenes, Kaurane - agonists | Chromosomes, Human, Pair 21 - genetics | Drug Synergism | RUNX1 Translocation Partner 1 Protein | Animals | Mice, Nude | Oncogene Proteins, Fusion - antagonists & inhibitors | Mice | Neoplasms, Experimental - metabolism | Neoplasms, Experimental - drug therapy | Drug Screening Assays, Antitumor | Index Medicus | Abridged Index Medicus | Neoplasia
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2014, Volume 32, Issue 32, pp. 3651 - 3658
Purpose The Children's Oncology Group study AHOD0031, a randomized phase III study, was designed to evaluate the role of early chemotherapy response in... 
TRIAL | MORTALITY | ABVD | POSITRON-EMISSION-TOMOGRAPHY | ONCOLOGY | INVOLVED-FIELD RADIATION | PEDIATRIC-PATIENTS | DISEASE | FOLLOW-UP | CHILDHOOD-CANCER SURVIVOR | NO RADIOTHERAPY | Cyclophosphamide - administration & dosage | Hodgkin Disease - pathology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Infant | Male | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Hodgkin Disease - radiotherapy | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Female | Child | Infant, Newborn | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Bleomycin - administration & dosage | Bleomycin - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Cisplatin - adverse effects | Vincristine - adverse effects | Doxorubicin - adverse effects | Index Medicus | Pedi9 | ORIGINAL REPORTS | Hema14
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 3, Issue 5, pp. e217 - e227
Summary Background Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk... 
Hematology, Oncology and Palliative Medicine | 1ST-LINE TREATMENT | RESPONSE CRITERIA | GUIDELINES | NON-HODGKINS-LYMPHOMA | FOLLOW-UP | CENTRAL-NERVOUS-SYSTEM | WHOLE-BRAIN RADIOTHERAPY | HIGH-DOSE CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Male | Comparative Effectiveness Research | Hyperglycemia - chemically induced | Radiotherapy, Adjuvant - adverse effects | Hematopoietic Stem Cell Transplantation - adverse effects | Lymphoma, B-Cell - diagnostic imaging | Transplantation Conditioning - methods | Rituximab - adverse effects | Induction Chemotherapy - methods | Anemia - chemically induced | Central Nervous System Neoplasms - therapy | Thrombocytopenia - chemically induced | Mucositis - chemically induced | Magnetic Resonance Imaging | Methotrexate - adverse effects | Dexamethasone - therapeutic use | Radiotherapy, Adjuvant - methods | Transplantation, Autologous - adverse effects | Heart Injuries - chemically induced | Italy | Hematopoietic Stem Cell Transplantation - methods | Central Nervous System Neoplasms - mortality | Germany | Thiotepa - adverse effects | Thiotepa - therapeutic use | Thrombosis - chemically induced | Intraocular Lymphoma - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Infection - chemically induced | Rituximab - therapeutic use | Stroke - chemically induced | Optic Nerve Neoplasms - diagnostic imaging | Poisoning - epidemiology | Female | Remission Induction - methods | Transplantation Conditioning - adverse effects | Acute Kidney Injury - chemically induced | Neutropenia - chemically induced | Optic Nerve Neoplasms - therapy | Death, Sudden - epidemiology | Lymphoma, B-Cell - mortality | Intraocular Lymphoma - diagnostic imaging | Kaplan-Meier Estimate | Chemical and Drug Induced Liver Injury - epidemiology | Treatment Outcome | United Kingdom | Combined Modality Therapy - adverse effects | Switzerland | Induction Chemotherapy - adverse effects | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Central Nervous System Neoplasms - diagnostic imaging | Denmark | Combined Modality Therapy - methods | Neurotoxicity Syndromes - epidemiology | Gastrointestinal Diseases - chemically induced | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2013, Volume 31, Issue 31, pp. 3971 - 3979
Journal Article
Blood, ISSN 0006-4971, 05/2012, Volume 119, Issue 20, pp. 4619 - 4624
Approximately 5-10% of diffuse large B-cell lymphomas (DLBCL) harbor a 8q24/MYC rearrangement (MYC+). We determined the prognostic significance of MYC... 
REARRANGEMENT | IMPACT | POOR-PROGNOSIS | T(14/18) | IN-SITU HYBRIDIZATION | CLASSIFICATION | HEMATOLOGY | EXPRESSION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Podophyllotoxin - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Cisplatin - administration & dosage | Young Adult | Lymphoma, Large B-Cell, Diffuse - therapy | Melphalan - adverse effects | Immunotherapy | Treatment Failure | Podophyllotoxin - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Carmustine - adverse effects | Genes, myc - physiology | Dexamethasone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Ifosfamide - adverse effects | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Cytarabine - administration & dosage | Lymphoma, Large B-Cell, Diffuse - mortality | Melphalan - administration & dosage | Ifosfamide - administration & dosage | Cisplatin - adverse effects | Aged | Hematopoietic Stem Cell Transplantation - methods | Antibodies, Monoclonal, Murine-Derived - adverse effects | Lymphoma, Large B-Cell, Diffuse - genetics | Carmustine - administration & dosage | Index Medicus | Abridged Index Medicus | Life Sciences | Biochemistry, Molecular Biology | Lymphoma, Large B-Cell, Diffuse | Podophyllotoxin | methods | Genes, myc | Cytarabine | genetics | administration & dosage | Melphalan | Antibodies, Monoclonal, Murine-Derived | Dexamethasone | drug therapy | Ifosfamide | Carmustine | therapy | Antineoplastic Combined Chemotherapy Protocols | Etoposide | physiology | Hematopoietic Stem Cell Transplantation | Cisplatin | adverse effects | mortality | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Blood, ISSN 0006-4971, 08/2017, Volume 130, Issue 6, pp. 722 - 731
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 09/2012, Volume 104, Issue 18, pp. 1386 - 1395
Treatment of acute lymphoblastic leukemia (ALL) has included the use of prophylactic cranial irradiation in up to 20% of children with high-risk disease... 
ATTENTION | LONG-TERM SURVIVORS | NEUROPSYCHOLOGICAL PERFORMANCE | ONCOLOGY | FRONTAL-CORTEX | DEVELOPMENTAL MODEL | BRAIN MATURATION | SEX-DIFFERENCES | WHITE-MATTER VOLUME | WORKING-MEMORY | CHILDREN | Multivariate Analysis | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Humans | Precursor Cell Lymphoblastic Leukemia-Lymphoma - psychology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Infant | Male | Cytarabine - adverse effects | Patient Selection | Hydrocortisone - administration & dosage | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Time Factors | Attention - drug effects | Vincristine - administration & dosage | Female | Child | Injections, Spinal | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Drug Administration Schedule | Risk Factors | Mercaptopurine - administration & dosage | Mercaptopurine - adverse effects | Logistic Models | Treatment Outcome | Cognition - drug effects | Cranial Irradiation - adverse effects | Remission Induction | Cytarabine - administration & dosage | Intelligence Tests | Methotrexate - adverse effects | Hydrocortisone - adverse effects | Adolescent | Sex Factors | Vincristine - adverse effects | Methotrexate - administration & dosage | Intelligence - drug effects | Care and treatment | Patient outcomes | Acute lymphocytic leukemia | Research | Cognition disorders | Risk factors | Cancer in children | Chemotherapy | Cognition & reasoning | Patients | Leukemia | Children & youth | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 21, pp. 3239 - 3246
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2014, Volume 167, Issue 3, pp. 394 - 401
Children and adolescents with B urkitt L ymphoma ( BL ) and combined central nervous system ( CNS ) and bone marrow involvement still have a poor prognosis... 
children | chemotherapy | urkitt lymphoma | rituximab | urkitt leukaemia | Rituximab | Chemotherapy | Burkitt leukaemia | Children | Burkitt lymphoma | ACUTE-LYMPHOBLASTIC-LEUKEMIA | PLUS RITUXIMAB | PHASE-II | RISK | ADULT BURKITT | B-CELL LYMPHOMA | CODOX-M/IVAC | THERAPY | NON-HODGKINS-LYMPHOMA | INTERMEDIATE | HEMATOLOGY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Consolidation Chemotherapy | Cytarabine - adverse effects | Genes, myc | Typhlitis - chemically induced | Lymphoma, B-Cell - genetics | Cyclophosphamide - adverse effects | Immunotherapy | Burkitt Lymphoma - genetics | Vincristine - administration & dosage | Female | Maintenance Chemotherapy | Child | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Lymphoma, B-Cell - drug therapy | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Drug Administration Schedule | Kaplan-Meier Estimate | Etoposide - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Marrow - pathology | Adolescent | Vincristine - adverse effects | Methotrexate - administration & dosage | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Central Nervous System Neoplasms - drug therapy | Doxorubicin - adverse effects | Lymphomas | Leukemia | Central nervous system | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1691 - 1699
Summary Background Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the... 
Hematology, Oncology and Palliative Medicine | AML | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | BONE-MARROW | CLASSIFICATION | FLT3 MUTATIONS | CYTARABINE | STEM-CELL TRANSPLANTATION | COMBINATION | ELDERLY-PATIENTS | CHEMOTHERAPY | Niacinamide - analogs & derivatives | Recurrence | Age Factors | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Transplantation, Homologous | Neoadjuvant Therapy - mortality | Time Factors | Phenylurea Compounds - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Chemotherapy, Adjuvant | Daunorubicin - therapeutic use | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Leukemia, Myeloid, Acute - diagnosis | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Germany | Antimitotic agents | Clinical trials | Chemotherapy | Antineoplastic agents | Standards | Cancer | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2010, Volume 363, Issue 26, pp. 2511 - 2521
In this study, adding pegylated interferon alfa-2a to imatinib therapy for chronic myeloid leukemia resulted in a greater reduction in the number of cells... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, GENERAL & INTERNAL | CHRONIC GRANULOCYTIC-LEUKEMIA | INTERFERON | POSITIVE CELLS | CHRONIC-PHASE | ABL TYROSINE KINASE | HEMATOPOIETIC STEM-CELLS | FOLLOW-UP | PATIENTS RECEIVING IMATINIB | CYTARABINE | Piperazines - administration & dosage | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Polyethylene Glycols - adverse effects | Male | Proto-Oncogene Proteins c-abl - analysis | Cytarabine - adverse effects | Recombinant Proteins | RNA, Neoplasm - analysis | Adult | Female | Transcription, Genetic | Neutropenia - chemically induced | Proto-Oncogene Proteins c-abl - genetics | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Anemia - chemically induced | Treatment Outcome | Thrombocytopenia - chemically induced | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Leukemia, Myeloid, Chronic-Phase - mortality | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - analysis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Stem Cells - drug effects | Interferon-alpha - adverse effects | Benzamides | Drug therapy | Chronic myeloid leukemia | Medical research | Kinases | Leukemia | Manuscripts | Index Medicus | Abridged Index Medicus
Journal Article